Document is current
Any future updates will be listed below
-
Authors
Gurule, Natalia J.
McCoach, Caroline E.
Hinz, Trista K.
Merrick, Daniel T.
Van Bokhoven, Adriaan
Kim, Jihye
Patil, Tejas https://orcid.org/0000-0003-4389-1010
Calhoun, Jacob
Nemenoff, Raphael A. https://orcid.org/0000-0002-2369-2535
Tan, Aik Choon https://orcid.org/0000-0003-2955-8369
Doebele, Robert C. https://orcid.org/0000-0001-6728-6857
Heasley, Lynn E. https://orcid.org/0000-0001-8056-0208
- License Information
-
More Information
Article History
Received: 3 September 2020
Accepted: 21 April 2021
First Online: 17 May 2021
Competing interests
: T.P.: Received honoraria from Roche/Genentech, PRIME Oncology, and Aptitude Health, LLC. R.C.D.: Advisory boards for Ignyta, Genentech/Roche, AstraZeneca, Takeda, Blueprint Medicines, Anchiano and Rain Therapeutics. Intellectual Property Licensing: Foundation Medicine, Rain Therapeutics, Abbott Molecular, Black Diamond, Pearl River, Voronoi. Stock Ownership: Rain Therapeutics. C.E.M.: Honoraria from Genentech, Novartis and Guardant Health. Research funding from Novartis and Revolution Medicines. The remaining authors declare that there are no other competing interests.
